Educational Resources
EDUCATIONAL RESOURCES
KYSCO 2025 Inmunotherapy Meeting
Click on the session titles to view the recordings.
View the Agenda and Recorded TalksView KYSCO Oncology Voices Podcasts
Help patients explore everything CAR T Cell Therapy
Posted on 11/12/2025
A patient and caregiver website to learn more and find resources about each step of the CAR T cell therapy journey. Visit www.explorecelltherapy.com or download the resource below to learn more.
Patient Out-of-Pocket (OOP) Costs for Covered Medicare Part D Drugs will be Capped in 2026
Posted on 11/12/2025
The Inflation Reduction Act of 2022 included several provisions to reduce OOP costs for Medicare Part D medicines:¹-3
In 2026, $2,100 is the total maximum OOP cost patients will pay for their covered Part D drugs. This includes their annual deductible.
Patients have the option to spread their OOP costs out over the course of the year by opting in to the Medicare Prescription Payment Plan.
CONSIDERATIONS FOR NEOADJUVANT AND ADJUVANT THERAPY
Posted on 11/12/2025
In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.
Best Practices and Solutions for Performing Bone Marrow Biopsies in AML Care
Bone marrow biopsies play a critical role in diagnosing, staging, and monitoring treatment response in AML. In this expert-led educational video, Thomas LeBlanc, MD, MA, MHS, hematologist-oncologist, associate professor of medicine and population health sciences at Duke Cancer Institute, and Keri Halsema, MSN, NP, nurse practitioner and senior instructor in the Cell Therapy Center at University of Colorado, walk through essential best practices for performing and interpreting bone marrow biopsies in AML care. Topics include key diagnostic tests, biopsy techniques, outpatient procedural considerations, and strategies to improve provider confidence through training and simulation. The video also highlights the importance of patient education, interdisciplinary coordination, and timely lab processing to support optimal outcomes.
Learn about CAR-T Cell Therapy in Earlier Lines of Treatment for Relapsed or Refractory Multiple Myeloma
Posted on 11/6/2025
To view the full publication, please refer to San-Miguel, J, et al. N Engl J Med. 2023;389(4):335-347 or click the resource below to view the Plain Language Summary of Publication of this article.
Pfizer | MyHealthcareFinances
Posted on 10/29/2025
MyHealthcareFinances is a freely available website to help patients and caregivers understand finances related to healthcare and steps that may lower costs. The site is a collaboration between Pfizer and Triage Cancer, joining people with a shared passion for improving healthcare-related financial literacy. Visit https://www.myhealthcarefinances.com/ for more information.
Pfizer Oncology Together
Posted on 10/29/2025
Live: Call 1-877-744-5675 (Monday–Friday 8 AM–8 PM ET)
Online: Visit http://PfizerOncologyTogether.com
Pfizer is committed to supporting patients throughout their treatment journey. With Pfizer Oncology Together, patients prescribed a Pfizer Oncology medication can get help identifying financial assistance options and be connected to resources that may help with some of their day-to-day challenges.
Pfizer Oncology Together can help healthcare providers by:
Assisting with benefits verification, prior authorizations, appeals, billing and coding, and specialty pharmacy coordination
Connecting them and their office staff to a Pfizer Field Reimbursement Manager (FRD) who can help address specific access and reimbursement issues—in person or over the phone
Offering and assisting with online portals that provide registered users with access and financial assistance resources
Pfizer Oncology Together can help patients by:
Connecting them with financial assistance resources—regardless of their insurance coverage
Providing personalized support from a Pfizer Oncology FRM who can help identify resources and organizations that may provide additional assistance
Please visit http://PfizerOncologyTogether.com for more details, or contact your local FRM or AP&R Director to learn more.
© 2024 Pfizer Inc. All rights reserved. PP-UNP-USA-4653 September 2024
Explore emerging real-world evidence in front-line BPDCN
This new publication explores real-world safety and efficacy in patients treated with a CD123 targeted therapy in newly diagnosed blastic plasmacytoid dendritic cell neoplasms.
A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)
Posted on 05/14/2025
Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine therapy in participants with node-positive ER+/HER2- early breast cancer with high risk of recurrence. The main purpose of this study is to compare the Invasive Breast Cancer-Free Survival (IBCFS) over a period of up to 5 years. 4220 participants will be included in this study around the world. Participants will have equal chance to be assigned to receive either of the treatment combinations.
Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)
Posted on 11/09/2024
Anemia is a hallmark of MDS, conferring heightened mortality risk and diminished quality of life. Please feel free to view & share this important resource.
